-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 31, Luye Pharma Group announced that its subsidiary Luye Pharma (Switzerland) entered into an agreement with Exeltis Pharma Mexico, SA de CV and Exeltis Pharmaceuticals Holding, SL (Exeltis) to grant the latter the Mindor Day Transdermal Patch in Lisbon.
Ristigmine Multi-Day Transdermal Patch is an innovative twice-weekly patch formulation of Ristigmine for the treatment of mild to moderate dementia associated with Alzheimer's disease
It is reported that the sales of Ristigmine multiday transdermal patch in the European market is the responsibility of the company's local branches and partners; the company also has the exclusive rights to develop and commercialize the product in Japan, as well as the exclusive rights in mainland China.
Alzheimer's disease is an irreversible neurodegenerative disease that causes progressive decline in memory and other cognitive aspects of patients
Note: The original text has been deleted